|Articles|February 26, 2009

FDA's FY 2009 Budget May Increase

Earlier this week, House Appropriations Committee Chairman Rep. David Obey (D-WI) introduced the FY 2009 Omnibus Appropriations Act (H.R. 1105).

Washington, DC (Feb. 26)-Earlier this week, House Appropriations Committee Chairman Rep. David Obey (D-WI) introduced the FY 2009 Omnibus Appropriations Act (H.R. 1105). Included in the proposed bill is $2.622 billion for the US Food and Drug Administration, approximately $511 million of which is to be derived from prescription drug user fees.

The Center for Drug Evaluation and Research may receive approximately $777 million for its activities and those of the Office of Regulatory Affairs (ORA), $41 million of which would go to the Office of Generic Drugs. The Center for Biologics Evaluation and Research may receive about $271 million for its activities and those of ORA.

In December 2007, Congress enacted the FY 2008 omnibus appropriations, which gave FDA $1.714 billion, and in June 2008, Congress gave the agency another $150 million as part of the FY 2008 emergency supplemental appropriations bill. FDA can use the $150 million through Sept. 30 of this year, according to the Alliance for a Stronger FDA.

Overall, the proposed nearly $2 billion in direct appropriations for FY 2009, ending Sept. 30, 2009, would be a few million more than FDA’s FY 2008 funding of approximately $1.7 billion. The full proposed appropriations bill is available online here.


Related to this article

CPHI Milan 2026: Trends in Pharma
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.